4basebio Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Heikki Lanckriet
Chief executive officer
UK£448.9k
Total compensation
| CEO salary percentage | 66.8% |
| CEO tenure | no data |
| CEO ownership | 9.8% |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -UK£6m |
| Mar 31 2023 | n/a | n/a | -UK£6m |
| Dec 31 2022 | UK£449k | UK£300k | -UK£5m |
| Sep 30 2022 | n/a | n/a | -UK£5m |
| Jun 30 2022 | n/a | n/a | -UK£4m |
| Mar 31 2022 | n/a | n/a | -UK£4m |
| Dec 31 2021 | UK£428k | UK£267k | -UK£3m |
| Sep 30 2021 | n/a | n/a | -UK£3m |
| Jun 30 2021 | n/a | n/a | -UK£2m |
| Mar 31 2021 | n/a | n/a | -UK£1m |
| Dec 31 2020 | UK£22k | UK£22k | -UK£719k |
Compensation vs Market: Heikki's total compensation ($USD560.84K) is about average for companies of similar size in the UK market ($USD775.47K).
Compensation vs Earnings: Heikki's compensation has increased whilst the company is unprofitable.
CEO
Heikki Lanckriet (46 yo)
no data
Tenure
UK£448,900
Compensation
Dr. Heikki Lanckriet, Ph.D. serves as Director at Biofrontera Inc. since July 07, 2023. He served as Member of Supervisory Board at Epigenomics AG since June 2022 until 2024. He serves as Non-executive Dir...